Live Research Database
Eczema
Hub: Indianapolis, IN
Connecting patients in Indianapolis with breakthrough clinical trials, specialized care, and study-related compensation.
+4k
Join 4,200+ participants tracking trials in Indiana
Available Eczema Opportunities
12 RecruitingNCT06863961(Verify)
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING
Eczema
NCT06807268(Verify)
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
RECRUITING
Eczema
NCT06807281(Verify)
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING
Eczema
NCT07006792(Verify)
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING
Eczema
NCT05995964(Verify)
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
RECRUITING
Eczema
NCT07265479(Verify)
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING
Eczema
NCT07230860(Verify)
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING
Eczema
NCT07217015(Verify)
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
RECRUITING
Eczema
NCT06241118(Verify)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
RECRUITING
Eczema
NCT06389136(Verify)
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING
Eczema
NCT06461897(Verify)
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING
Eczema
NCT06988605(Verify)
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
RECRUITING
Eczema
Patient Safeguards
IRB Oversight
Ethics Committee Approved
HIPAA Compliant
Full Data Privacy
NIH Standards
Global Quality Benchmarks
"Advancing Eczema research in Indianapolis through safe, transparent, and patient-first clinical trials."
Research Hubs in Indianapolis
Explore other local breakthroughs
Eczema Hubs in IN
Regional Network of Excellence
ClinicalTrials.govFDA REGISTEREDIRB OVERSIGHTHIPAA COMPLIANT